EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy

Rebecca Shepherd, Lachlan M Angus, Toby Mansell, Bridget Arman, Bo Won Kim, Katherine Lange, David Burgner iD, Jessica A Kerr, Ken Pang iD, Jeffrey D Zajac, Richard Saffery iD, Ada Cheung iD und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae226 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Rebecca Shepherd und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Immunity, Infection and Immunity Theme, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia. Hauptthemen laut MEDLINE: Androgen Antagonists, Metabolome, Cyproterone Acetate, Transgender Persons. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHMRC, Australian Government Research and Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The plasma metabolome is a functional readout of metabolic activity and is associated with phenotypes exhibiting sexual dimorphism, such as cardiovascular disease. Sex hormones are thought to play a key role in driving sexual dimorphism.

Objective

Gender-affirming hormone therapy (GAHT) is a cornerstone of transgender care, but longitudinal changes in the plasma metabolome with feminizing GAHT have not been described.

Methods

Blood samples were collected at baseline and after 3 and 6 months of GAHT from transgender women (n = 53). Participants were randomized to different anti-androgens, cyproterone acetate or spironolactone. Nuclear magnetic resonance-based metabolomics was used to measure 249 metabolic biomarkers in plasma. Additionally, we used metabolic biomarker data from an unrelated cohort of children and their parents (n = 3748) to identify sex- and age-related metabolite patterns.

Results

We identified 43 metabolic biomarkers altered after 6 months in both anti-androgen groups, most belonging to the very low- or low-density lipoprotein subclasses, with all but 1 showing a decrease. We observed a cyproterone acetate-specific decrease in glutamine, glycine, and alanine levels. Notably, of the metabolic biomarkers exhibiting the most abundant “sex- and age-related” pattern (higher in assigned female children and lower in assigned female adults, relative to assigned males), 80% were significantly lowered after GAHT, reflecting a shift toward the adult female profile.

Conclusion

Our results suggest an anti-atherogenic signature in the plasma metabolome after the first 6 months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsMetabolomeCyproterone AcetateTransgender PersonsBiomarkersHumansFemaleMaleAdultYoung AdultGender-Affirming ProceduresSpironolactoneChildMetabolomicsAdolescentTranssexualismHormone Replacement TherapyMiddle Aged

Stichwörter der Autor:innen

GAHTestradiolmetabolismmetabolomesex hormonestransgender

Substanzen

Androgen AntagonistsCyproterone AcetateBiomarkersSpironolactone

Autor:innen und Institutionen

  • Molecular Immunity, Infection and Immunity Theme, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia.
  • Department of Medicine (Austin Health), The University of Melbourne, Parkville, VIC 3052, Australia.
  • Department of Endocrinology, Austin Health, Heidelberg, VIC 3084, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia.
  • Inflammatory Origins, Infection and Immunity Theme, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia.
  • Therapeutics Discovery and Vascular Function Group, Department of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, VIC 3084, Australia.

ORCID-Profile: David Burgner, Ken Pang, Richard Saffery, Ada Cheung, Boris Novakovic

Förderung

  • NIAID NIH HHS
  • NHMRC
  • Australian Government Research and Training Program
  • National Institute of Allergy And Infectious Diseases
  • National Health and Medical Research Council

Zitieren

APA

Shepherd, R., Angus, L. M., Mansell, T., Arman, B., Kim, B. W., Lange, K., Burgner, D., Kerr, J. A., Pang, K., Zajac, J. D., Saffery, R., Cheung, A., & Novakovic, B. (2024). Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae226

Vancouver

Shepherd R, Angus LM, Mansell T, Arman B, Kim BW, Lange K, et al. Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae226

BibTeX
@article{Shepherd2024,
  author = {Shepherd, Rebecca and Angus, Lachlan M and Mansell, Toby and Arman, Bridget and Kim, Bo Won and Lange, Katherine and Burgner, David and Kerr, Jessica A and Pang, Ken and Zajac, Jeffrey D and Saffery, Richard and Cheung, Ada and Novakovic, Boris},
  title = {Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae226}
}
Kostenlos starten →